The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Mezavant XL 1200 mg gastro-resistant, prolonged release tablets



Takeda Pharmaceuticals International AG Ireland BranchPA23211/004/001

Main Information

Trade NameMezavant XL 1200 mg gastro-resistant, prolonged release tablets
Active SubstancesMesalazine
Dosage FormProlonged-release tablet
Licence HolderTakeda Pharmaceuticals International AG Ireland Branch
Licence NumberPA23211/004/001

Group Information

ATC CodeA07EC Aminosalicylic acid and similar agents
A07EC02 mesalazine

Status

License statusAuthorised
Licence Issued23/02/2007
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back